Emerald Advisers’s Biogen BIIB Stock Holding History

Emerald Advisers’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.1M	Hold	6,027	–	–	0.04%	141
2025 Q4	$1.06M	Sell	6,027 -220	-4%	-$35.9K	0.03%	137
2025 Q3	$875K	Buy	6,247 +3,066	+96%	+$414K	0.03%	148
2025 Q2	$400K	Buy	+3,181	New	+$396K	0.01%	191

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Emerald Advisers's BIIB Position: Q1 2026 in Review

Emerald Advisers held its Biogen (BIIB) position steady in Q1 2026 at 6,027 shares worth $1.1M. The position accounts for 0.04% of the portfolio, ranked #141.

Emerald Advisers first reported a position in BIIB in Q2 2025 and has held it in 4 quarters since. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Emerald Advisers held 6,027 shares of Biogen worth $1.1M as of Q1 2026.
Emerald Advisers left its Biogen share count unchanged in Q1 2026.
Biogen made up 0.04% of Emerald Advisers's portfolio in Q1 2026, its #141 holding.
Emerald Advisers first reported a position in Biogen in Q2 2025 and has held it in 4 quarters since.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Emerald Advisers's 13F filing for Q1 2026, filed 4 May 2026.